SEARCH

SEARCH BY CITATION

References

  • 1
    Kiel DP, Magaziner J, Zimmerman S, Ball L, Barton BA, Brown KM, Stone JP, Dewkett D, Birge SJ. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. JAMA. 2007; 298(4): 413422.
  • 2
    Barton BA, Birge SJ, Magaziner J, Zimmerman S, Ball L, Brown KM, Kiel DP. The Hip Impact Protection Project: design and methods. Clin Trials. 2008; 5(4): 347355.
  • 3
    Kannus P, Parkkari J. Hip protectors for preventing hip fracture. JAMA. 2007; 298(4): 454455.
  • 4
    Bauchner H, Fontanarosa PB. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. (Editorial about 2007 article [1]) JAMA. 2012; 308(23): 2519.
  • 5
    OHRP letter of June 23, 2011, in re: Human Research Protections under Federalwide Assurances FWA-00000885, FWA-00002284 and FWA-00007145. http://www.hhs.gov/ohrp/detrm_letrs/YR11/jun11a.pdf. Accessed November 5, 2012.
  • 6
    Batt DB, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsky P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo D, Genereux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA. Effect of platelet inhibition with Cangrelor during PCI on ischemic events. NEJM 2013; 368(14): 13031313.
  • 7
    Shuster JJ. Practical Handbook of Sample Size Guidelines for Clinical Trials. 1992. Boca Raton, FL: CRC Press.